BCAL Diagnostics Limited (ASX:BDX)
Australia · Delayed Price · Currency is AUD 0.0860
+0.0160 (22.86%)
Sep 17, 2026, 3:34 PM AEST
BCAL Diagnostics Company Description
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia.
It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test.
The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited
| Country | Australia |
| Founded | 2010 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Anne-Louise Arnett |
Contact Details
Address: 50 Clarence Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9078 7671 |
| Website | bcaldiagnostics.com |
Stock Details
| Ticker Symbol | BDX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000160921 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anne-Louise Arnett | Chief Executive Officer |
| Jayne Andrea Shaw | Co-Founder and Executive Chairman |
| Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | Chief Financial Officer and Company Secretary |
| Sean Alexander Kennedy | Director of Corporate Finance |
| Alexandra Feetham | Head of Innovation |